AbCellera Biologics (ABCL) Stock Statistics & Valuation Metrics

AbCellera Biologics has a market cap or net worth of $588.01M. The enterprise value is ―.

AbCellera Biologics has 298,484,650 shares outstanding. The number of shares has decreased by -2.65% in one year.

AbCellera Biologics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -19.92%.

The current PE Ratio of AbCellera Biologics is -5.30. AbCellera Biologics’s PEG ratio is -0.63.

In the last 12 months, AbCellera Biologics had revenue of 28.83M and earned -162.86M in profits. Earnings per share was -0.55.

In the last 12 months, operating cash flow was -108.05M and capital expenditures -78.08M, giving a free cash flow of -186.13M billion.

AbCellera Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

AbCellera Biologics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.

AbCellera Biologics as a current ratio of 9.81, with Debt / Equity ratio of 5.75%

In the past 12 months, AbCellera Biologics has paid -37.54M in taxes.

AbCellera Biologics EV to EBITDA ratio is -3.76, with an EV/FCF ratio of -4.10.

AbCellera Biologics has $625.61M in cash and marketable securities with $60.74M in debt, giving a net cash position of -$564.87M billion.

Gross margin is -188.19%, with operating margin of -1091.69%, and net profit margin of -564.83%.

The average price target for AbCellera Biologics is $7.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy